<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274870</url>
  </required_header>
  <id_info>
    <org_study_id>IRB: 14-237B</org_study_id>
    <nct_id>NCT02274870</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery</brief_title>
  <official_title>Liposomal Bupivacaine for Total Knee Arthroplasty Postoperative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous femoral nerve blocks (CFNB) provide effective pain control to patients undergoing
      total knee replacement (TKR). However the resulting motor blockade can lead to decreased
      quadriceps muscle strength and delayed functional recovery.The purpose of this study is to
      compare the effect of Liposome Bupivacaine infiltration into the knee to CFNB on pain control
      and functional recovery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, active controlled study in patients undergoing total knee
      replacement. The objective of this study is to compare the efficacy of Liposome Bupivacaine,
      in managing postoperative pain, to standard of care CFNB. Following informed consent,
      patients will be randomized to one of two groups, Liposome Bupivacaine or active control,
      CFNB group.

      266 mg Liposome Bupivacaine plus Bupivicaine HCL (150mg) will be administered via local joint
      infiltration around the knee joint prior to wound closure. In the control group a CFNB will
      be placed for 48hrs prior to surgery. Outcomes measured included pain at rest, movement and
      quadriceps muscle strength on the first and second postoperative day.

      It is hypothesized that Liposome Bupivacaine will provide effective pain control and improved
      preservation of quadriceps muscle strength, in comparison to CFNB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain at movement</measure>
    <time_frame>72hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quadriceps muscle strength</measure>
    <time_frame>72hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest</measure>
    <time_frame>72hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma bupivicaine levels</measure>
    <time_frame>48hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Liposome Bupivacaine,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposome Bupivacaine 266mg, Knee Infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposome Bupivacaine</intervention_name>
    <description>Administered via local tissue infiltration around the knee joint</description>
    <arm_group_label>Liposome Bupivacaine,</arm_group_label>
    <other_name>Bupivacaine Liposome, Injectable Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Administered via CFNB</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <other_name>Standard of Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA Status I-III

          -  Scheduled to undergo primary unilateral total knee arthroplasty

        Exclusion Criteria:

          -  Patients who are pregnant or nursing

          -  Alcohol or narcotic dependence within the last 2 years

          -  Condition requiring regular use of analgesia that may confound post surgical
             assessments as determined by principle investigator

          -  BMI &gt; 40kg/m2

          -  Contraindication to acetaminophen, morphine, oxycodone, ketorolac, epinephrine, or
             pathological conditions potentially aggravated by epinephrine

          -  Allergies to amide-type local anesthetics

          -  Any disease condition or lab result that could complicate a patients postoperative
             recovery

          -  History of hypotension

          -  Abnormal liver, renal or cardiac function

          -  Other physical, mental or medical conditions that, in the opinion of the investigator,
             make study participation inadvisable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Marino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franklin</name>
      <address>
        <city>Valley stream</city>
        <state>New York</state>
        <zip>11580</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Joseph Marino M.D.</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>February 22, 2018</submitted>
    <returned>March 19, 2018</returned>
    <submitted>April 11, 2018</submitted>
    <returned>May 11, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

